An interventional study of vestibular implant in Vestibulopathy, Moderate to Severe Hearing Loss and Normal Hearing, sponsored by Cochlear. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by Cochlear · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Hearing Loss by Cochlear — 5 open to participants now, 12 under way, none of them phase 3. Hearing Loss · Cochlear.
Among the 50 studies in Hearing Loss by Cochlear, this one is the 33rd largest by planned enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2025, is one of 43 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 44th registered.
797 studies on the registry are indexed under Hearing Loss; 195 are open to participants now.
Browse Hearing Loss studies →5 of the 50 studies in Hearing Loss by Cochlear are open now, in 6 countries. Recruiting first, the newest first:
Cochlear · Sites in Belgium, Netherlands
Ages 18+
Cochlear · Sites in Australia
Ages 18+
Cochlear · Sites in Germany
Ages 18+
Cochlear · Sites in United States, Australia
Ages 18+
By country, each count listing its studies:
Of the 125 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 43 (34%) stop at 75 or younger; 47 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 44 across 562 interventional studies indexed under Hearing Loss.
Median enrollment 32 across the 43 interventional studies, 153 across the 7 observational. Of the 37 that completed or were terminated, 27 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cochlear is the lead sponsor of 92 studies on the registry; 9 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
6 of the studies in Hearing Loss by Cochlear that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07139327CochlearA Pivotal Study to Evaluate the Efficacy and Safety of a Totally Implantable Cochlear Implant (TICI) System in Adults | 2027-04 |
| NCT06098482CochlearAn Investigation to Validate Speech Perception Assessment for Adult Cochlear Recipients Using a Mobile Research App | 2027-05-02 |
| NCT06805175CochlearA Study to Evaluate the Safety and Performance of a Vestibular Implant in Adults to Provide Balance Restoration | 2027-06 |
| NCT06641999CochlearEvaluating How a Tinnitus Implant Affects Tinnitus Loudness in Adults With Chronic Tinnitus and Varying Levels of Hearing Loss | 2027-07 |
| NCT07287124CochlearA Pivotal Study to Evaluate the Clinical Benefit, Performance and Safety of a Totally Implantable Cochlear Implant (TICI) System in Adults | 2027-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies in Hearing Loss by Cochlear, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main aim of this study is to understand if an experimental vestibular implant system can improve balance performance. The system consists of a vestibular implant combined with a cochlear implant sound processor and programming software. The implant is designed to preserve hearing in the implanted ear. The vestibular implant is surgically placed under the skin just behind the ear in the mastoid bone and has an electrode that stimulates the vestibular nerve. A sound processor is worn behind the ear and powers the implant via the coil. The study will be conducted in adults with bilateral vestibulopathy (BVP) who have normal to severe hearing loss in the inner ear. The study participants will undergo a series of tests that include evaluations of their balance and hearing and self-reported questionnaires on their balance and general health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Hearing impairment ranging from:
Patients diagnosed with bilateral vestibulopathy or probable bilateral vestibulopathy based on the consensus document of the Barany Society on vestibular implant candidate criteria for research [van de Berg et al., 2020]:
a. Unsteadiness when walking or standing plus at least one of the following: i. Movement-induced blurred vision or ii. Oscillopsia during walking or quick head/body movements, and/or iii. Worsening of unsteadiness in darkness and/or on uneven ground b. Symptoms greatest during head movement and not compensated after rehabilitation program. c. Bilaterally reduced or absent angular VOR function documented by at least one of the following major criteria: i. Pathological horizontal angular VOR gain ≤ 0.6 and at least one vertical angular VOR gain \< 0.7, measured by the video-HIT technique. ii. Reduced caloric response (sum of bithermal max. peak SPV on each side ≤6◦/sec for 30 sec water stimuli or \<10◦/sec for 60 sec of air stimuli). In case only one of two criteria from c. are matched, the remaining test(s) should comply with the following minor criteria: 1) Bilaterally pathological VOR gains of at least two semicircular canals \< 0.7, measured by the video- HIT or scleral-coil technique 2) Reduced caloric response (sum of bithermal max. peak SPV on each side \<10°/sec for water and air stimuli of ≥30 sec). d. Absent cVEMP and oVEMP responses in the ear to be implanted.
vestibule permeability ascertained and present intact vestibular nerve.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: vestibular implant
vestibular implant
Change in Dynamic Gait Index (DGI) score from baseline to six months post-activation of the vestibular implant
Change in Dynamic Gait Index (DGI) score. Score range (0-24). Higher score means better outcome.
Time frame: Baseline (pre-surgery) to 6 months post implantation
Change in Functional Gait Assessment (FGA) score from baseline to six months post-activation of the vestibular implant
Change in Functional Gait Assessment (FGA) score. Score range (0-30). Higher score means better outcome.
Time frame: Baseline (pre-surgery) to 6 months post implantation
Change in Posturography - Sensory Test score from baseline to six months post-activation of the vestibular implant
Change in Posturography - Sensory Organization Test score. Score range (0-100%). Higher score means better outcome.
Time frame: Baseline (pre-surgery) to 6 months post implantation
Change in Posturography - Limits of Stability test score from baseline to six months post-activation of the vestibular implant
Change in Posturography - Limits of Stability test score. Scale range (0-100). Higher score means better outcome.
Time frame: Baseline (pre-surgery) to 6 months post implantation
Change in Dizziness Handicap Inventory (DHI) score from baseline to six months post-activation of the vestibular implant
Change in Dizziness Handicap Inventory (DHI) score. Score range (0-100). Higher score means worse outcome.
Time frame: Baseline (pre-surgery) to 6 months post implantation
Change in Fall Efficacy Scales International (FES-I) score from baseline to six months post-activation of the vestibular implant
Change in Fall Efficacy Scales International (FES-I) score. Score range (16-64). Higher score means worse outcome.
Time frame: Baseline (pre-surgery) to 6 months post implantation
Device or procedure related adverse events in participants up to six months post-activation of the vestibular implant.
Listing of device or procedure related adverse events.
Time frame: Baseline (pre-surgery) to 6 months post implantation
Change in hearing thresholds up to six months post-activation of the vestibular implant
Pre- vs post-surgery hearing thresholds difference (dB HL) measured at 250, 500, 1000, 2000, 4000, and 8000 Hz.
Time frame: Baseline (pre-surgery) to 6 months post implant surgery
Change in EuroQol 5D (EQ5D-5L) quality of life score from baseline to six months post-activation of the vestibular implant
Change in EuroQol 5D (EQ5D-5L) quality of life score. Score range (-0.594-1). Higher score means better outcome.
Time frame: Baseline (pre-surgery) to 6 months post implantation
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Jun 2027, 21 months after the start.
Of 126 industry-sponsored interventional studies with no phase under Hearing Loss, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's planned 21 months is above that.
Counting every sponsor, half of 323 studies reached it within 19 months; a quarter within 5 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.